69 results about "Platelet inhibition" patented technology

The invention relates to the technical field of coating surface preparation, in particular to an anticoagulant coating based on novel tick-derived anticoagulant protein Qinghaenin and a preparation method of the anticoagulant coating. The functional layer of the anticoagulant coating comprises the following components: anticoagulant protein Qinghaenin or a functional peptide fragment Qinghaenin 167-192 of the anticoagulant protein Qinghaenin, wherein the amino acid sequence of the functional peptide fragment is as shown in SEQ ID NO. 2. The preparation method of the anticoagulant coating comprises the following steps: by using a polydopamine coating as a substrate layer, covalently grafting through an amido bond, immobilizing anticoagulant protein Qinghaenin capable of inhibiting FXII factor activation or a functional peptide fragment Qinghaenin 167-192 thereof on the surface of a medical polymer material, and successfully constructing a novel anticoagulant coating. Compared with an unmodified medical polymer material, the modified coating can significantly enhance the hydrophilic performance of the material and inhibit platelet adhesion and activation, finally effectively prolongs the in-vitro blood coagulation time, and shows excellent anticoagulation performance.

The invention relates to a polypeptide derivative for pancreas islet surface modification and inhibition of pancreas islet transplantation IBMIR reaction, and belongs to the technical field of biological medicine. The peptide derivative disclosed by the invention is obtained by carrying out an amide reaction on KF7 peptide and levodopa, and the amino acid sequence of the KF7 peptide is shown as SEQ ID NO: 1. The polypeptide derivative has good biocompatibility, the surface modification method is simple, the modification process has no influence on cell life activity, activation, aggregation, expansion and adhesion of platelets can be inhibited, the bleeding risk is reduced, a blood coagulation system is not influenced, pancreas islet intrahepatic colonization and pancreas islet functions after portal transplantation are enhanced, and the application prospect is wide. The composition can protect pancreas islet, prevent infiltration of platelets and CD11b + cells, inhibit pancreas islet transplantation IBMIR reaction, control blood sugar level, and prevent and treat diabetes mellitus.

The present application relates to the technical field of resin preparation, and relates to a preparation method of an anticoagulant superabsorbent resin, which comprises the following steps: combining hydrolyzed tannic acid and nanocellulose through an oxidative coupling reaction, loading citric acid to obtain an anticoagulant compound; dissolving acrylic acid, sulfonated lignin, the anticoagulant compound, polylactic acid-diacrylate, azodicarboxamide, nanosilica and a photoinitiator in water to obtain a mixed solution; injecting the mixed solution into a microchannel reactor to perform a polymerization reaction under irradiation of pulsed ultraviolet light, so as to obtain a superabsorbent resin gel; immersing the superabsorbent resin gel in a polylactic acid-diacrylate solution, performing surface crosslinking through ultraviolet light irradiation, drying and grinding, so as to obtain anticoagulant superabsorbent resin particles; and the present application can inhibit platelet aggregation, delay the start of the coagulation cascade reaction, block the activation of coagulation factors, effectively prolong the blood clotting time, and provide a more sufficient liquid absorption window for the superabsorbent resin.

The invention discloses a traditional Chinese medicine composition for reinforcing qi, nourishing blood and strengthening body resistance after tumor chemoradiotherapy and a detection method thereof. The traditional Chinese medicine composition is prepared from astragalus membranaceus, codonopsis pilosula, angelica sinensis, poria cocos, cistanche, caulis spatholobi, radix paeoniae alba, glossy privet fruit, eclipta, hairyvein agrimony, medlar, Chinese yam, radix rehmanniae, radix ophiopogonis, deer-horn glue, tortoise-shell glue, pericarpium citri reticulatae and liquorice. The optimal traditional Chinese medicine composition and dosage are screened out through a large number of experimental screening and clinical medication experience, treatment is conducted on the basis of syndrome differentiation, compatibility is reasonable, the effects of reinforcing qi, nourishing blood and strengthening the body resistance are achieved together, immunity is improved, and the traditional Chinese medicine composition can be used for tumor chemoradiotherapy and postoperative conditioning and treatment of symptoms such as anemia, bone marrow suppression, thrombocytopenia and elderly weakness. Content determination is carried out through TLC identification and HPLC, and a scientific basis is provided for guaranteeing the clinical quality and effectiveness of reinforcing qi, nourishing blood and strengthening body resistance.

A series of sofalcone derivatives are provided.SOLUTION: A series of sofalcone derivatives provided by the present invention are, for example, compounds having a structure of formula (I), and have platelet aggregation inhibitory and antithrombotic effects. The sofalcone derivatives of the present invention are TxA2 receptor antagonists, have an inhibitory effect on platelet agglutination, and do not easily affect the hemostatic function. The present invention also provides a method for preparing the sofalcone derivative, and a method for using the sofalcone derivative for preventing or treating thrombotic diseases, or for inhibiting platelet aggregation.SELECTED DRAWING: None

Methods of inhibiting platelet activation and aggregation using peptide vaccines having binding specificity for the α subunit of the (Na++K+)-ATPase are provided, along with methods for inhibiting or preventing or treating thrombosis without causing bleeding.

The invention belongs to the technical field of biological medicine, and relates to an anticoagulant, in particular to an anticoagulant for a high-precision animal blood cell analyzer and application of the anticoagulant in leukocyte classification. The anticoagulant comprises a buffer and anticoagulation matrix component and an active component, wherein in every 100 mL of the anticoagulant, the buffer and anticoagulation matrix component formula comprises 1.5 to 2 g of citrate, 0.3 to 0.5 g of citric acid and 0.15 to 0.20 g of EDTA-K2 (Ethylene Diamine Tetraacetic Acid), and the active components comprise 0.08 to 0.10 g of low molecular weight enzymolysis carboxymethyl chitosan, 1.0 to 1.2 g of hydroxypropyl-beta-cyclodextrin, 10 to 15 mg of dipyridamole and 8 to 10 mg of aspirin. The anticoagulant effectively inhibits platelet activation, prevents platelet aggregation and leukocyte morphological deformation, realizes accurate identification in leukocyte five-classification, has a classification accuracy rate of 98%, and is suitable for veterinary clinical hematology examination and animal epidemic disease monitoring.

The invention provides a composition for improving the thrombolysis capacity of a human body, a preparation method and application thereof.The composition is prepared from, by weight, 5-30 parts of earthworm protein, 30-120 parts of hippophae rhamnoides total flavone extract, 50-150 parts of silymarin extract, 20-80 parts of maltodextrin and 15-60 parts of pregelatinized starch, the earthworm protein activates a fibrinolytic system to promote t-PA to release and dissolve thrombus, and the hippophae rhamnoides total flavone extract activates the fibrinolytic system to promote t-PA to release and dissolve thrombus; the hippophae rhamnoides total flavonoids regulate the ratio of PGI2 / TXA2 to inhibit platelet aggregation and reduce blood fat, the silymarin protects the liver function to enhance LDL-C metabolism clearing, the hippophae rhamnoides total flavonoids, the silymarin and the hippophae rhamnoides total flavonoids cooperate to form a thrombolysis-antithrombosis-metabolism regulation three-dimensional intervention system, a whole-course low-temperature mixing direct tabletting process is adopted

The application belongs to the technical field of biological medicine, and relates to an anticoagulant and application thereof in white blood cell classification for high-precision animal blood cell analyzers. The anticoagulant comprises two parts of buffer and anticoagulant matrix components and active components. In the anticoagulant, the buffer and anticoagulant matrix component formula comprises 1.5-2 g of citrate, 0.3-0.5 g of citric acid and 0.15-0.20 g of EDTA-K2 per 100 mL of the anticoagulant, and the active component comprises 0.08-0.10 g of low-molecular enzymatic hydrolysis carboxymethyl chitosan, 1.0-1.2 g of hydroxypropyl-beta-cyclodextrin, 10-15 mg of dipyridamole and 8-10 mg of aspirin. The anticoagulant effectively inhibits platelet activation, prevents platelet aggregation and white blood cell morphological deformation, accurately identifies in white blood cell five classification, and has a classification accuracy as high as 98%, and is suitable for veterinary clinical hematology examination and animal disease monitoring.

The objective is to provide a method that suppresses the formation of pseudopods of platelets during the preparation of PRP, thereby preventing the formation of aggregates. [Solution] The method for producing platelet-rich plasma (PRP) according to the present invention is characterized by adding a local anesthetic to the blood when producing PRP.

The application relates to the technical field of coating surface preparation, in particular to an anticoagulant coating based on a novel tick-derived anticoagulant protein Qinghaienin and a preparation method thereof. 167‑192 Wherein the amino acid sequence of the functional peptide segment is shown in SEQ ID NO. 2. The anticoagulant coating is prepared by using a polydopamine coating as a base layer, and then covalently grafting the anticoagulant protein Qinghaienin or the functional peptide segment Qinghaienin 167‑192 which can inhibit the activation of the FXII factor is covalently grafted through an amide bond to the surface of a medical polymer material, and a novel anticoagulant coating is successfully constructed. Compared with unmodified medical polymer materials, the modified coating can significantly enhance the hydrophilicity of the material, inhibit platelet adhesion and activation, effectively prolong the blood clotting time in vitro, and exhibit excellent anticoagulant performance.

The invention relates to a blood pump with a microstructure super-hydrophobic surface, which comprises a blade and a super-hydrophobic coating coated on the surface of the blade, and a micron-sized periodic pit array is etched on the surface of the blade through a femtosecond laser texturing technology to form a microstructure. A micron-sized periodic pit array is etched on an interface, in contact with blood, of a blood pump through a femtosecond laser texturing technology, so that a bionic micro-nano composite structure is formed; and a super-hydrophobic functional layer is constructed on the surface of the microstructure by further adopting a multi-scale coating technology (including but not limited to a plasma enhanced chemical vapor deposition method, a high-speed oxygen fuel thermal spraying method, a photoetching template guided self-assembly method and a directional electrostatic spinning method). Zero damage of blood cells under the dynamic shearing condition can be achieved, meanwhile, platelet adhesion and blood coagulation factor activation are effectively inhibited, and a breakthrough solution is provided for solving related complications of artificial heart clinical application.

This invention relates to the field of biomedicine, specifically to the application of banana fruit extract in the preparation of anticoagulant or antithrombotic drugs. The banana fruit extract provided by this invention contains flavonoids, polyphenols, polysaccharides, hydroxyanthraquinones, triterpenoids, and other components. Flavonoids and polyphenols have been widely proven to have anti-inflammatory and antioxidant effects, which can synergistically enhance the anticoagulant effect. The high potassium content of banana fruit can indirectly improve vascular function by regulating sodium-potassium balance. The banana fruit extract provided by this invention can inhibit platelet production or promote platelet metabolism, prolong clotting time, and inhibit platelet aggregation. Its natural plant components interfere with platelet aggregation by inhibiting the production of thromboxane A2, achieving anticoagulant and antithrombotic effects. The mechanism of action of banana fruit extract differs from traditional anticoagulants such as heparin, reducing the risk of bleeding. Its natural component characteristics provide a direction for the development of novel plant-derived anticoagulant drugs.

The invention discloses application of a compound in preparation of a medicine for treating or relieving ADPGK activation related concurrent diseases in chronic kidney diseases. The compound is found to be capable of effectively inhibiting the activity of ADPGK through computer virtual screening in combination with an in-vitro platelet activation experiment. In CKD patient and mouse models, the Z809269780 significantly reduces the glycolysis flux of platelets, lactic acid generation and RHOA lactylation level, thereby inhibiting the excessive activation and high reactivity of the platelets, and effectively relieving thrombosis events (such as platelet aggregation, adhesion, blood clot retraction and arterial thrombosis). Animal experiments show that intraperitoneal injection of the Z809269780 (10 mg / kg) has a good antithrombotic effect, and the Z809269780 does not show obvious toxicity under the dosage of 20 mg / kg. The invention provides a safe and effective novel targeted treatment strategy for preventing thrombotic complications of CKD patients.

The present invention relates to using c-Src SH3 RT-loop as a target for anti-thrombosis. Specifically, the present invention provides the use of a c-Src SH3 RT-loop antagonist for preparing a composition or preparation, and the composition or preparation is used for: (a) interfering with the interaction between integrin β3 and c-Src; (b) inhibiting platelet spreading on solid-phase fibrinogen; (c) inhibiting platelet aggregation and / or adhesion; and / or (d) preventing and / or treating thrombosis. The present invention discovers for the first time that a drug combination or preparation targeting the RT-loop region of the c-Src SH3 domain can effectively treat thrombotic diseases without increasing the risk of bleeding.

The present invention relates to the technical field of the biopharmaceutical industry, and specifically to a Platycladus orientalis leaf extract and a preparation method thereof, comprising the following raw materials: a modified Platycladus orientalis leaf extract, a modified total saponin of Panax notoginseng, Panax notoginseng, fibrin, chitosan, iron oxide, glycerol, and a modified spinach solution. In the present invention, the modified Platycladus orientalis leaf extract, the modified total saponin of Panax notoginseng, and the modified spinach solution work together through a synergistic effect. The modified Platycladus orientalis leaf extract contains a relatively high amount of volatile oil, which can stimulate platelet aggregation and promote the release of coagulation factors. The modified total saponin of Panax notoginseng can inhibit excessive platelet activation and aggregation, preventing thrombosis. The modified Platycladus orientalis leaf extract and the modified total saponin of Panax notoginseng can jointly promote platelet aggregation and the release of coagulation factors to accelerate blood coagulation. The modified spinach solution promotes the synthesis and release of coagulation factors by providing vitamin K, thereby accelerating blood coagulation. The three form a dynamic equilibrium system, which promotes blood coagulation through a synergistic effect, achieving a hemostatic effect.

The present application relates to a kind of preservative solution for prolonging the in vitro storage period of platelet and its preparation method, containing baicalin 4.50~6.00g, baicalein 3.00~3.40g, sodium citrate 1.50~2.00g, citric acid 0.20~0.50g, glucose 7.90~8.50g per liter of preservative solution, and the remaining component is distilled water.The preservative solution of the present application adds a certain proportion of baicalin and baicalein, and the composition has a synergistic effect on inhibiting platelet activation, protection and inhibition of platelet aggregation, can prolong the in vitro platelet normal temperature storage time, and the normal temperature storage time can reach 16d.

The present disclosure relates to compounds which exhibit activity in the inhibition of platelet aggregation as well as pharmaceutical compositions comprising these compounds and methods of treatment of vascular diseases by administration of these compounds or the pharmaceutical compositions.

The present application relates to the field of biomaterials, and particularly relates to a biomimetic biological valve. The biomimetic biological valve is obtained by wrapping a non-crosslinked biological basement membrane around a crosslinked extracellular matrix material to form a sandwich structure. The basement membrane cooperates with the crosslinked extracellular matrix material, fully plays the excellent regenerative repair performance and the characteristics of being rich in bioactive factors of the basement membrane, effectively promotes the growth and adhesion of endothelial cells on the surface of the material, and constructs a tissue structure similar to the natural valve leaflet. The biomimetic biological valve exhibits excellent anti-calcification performance and excellent dynamic mechanical stability and compliance, significantly inhibits the abnormal adhesion of platelets and blood cells, greatly improves the recovery and reconstruction efficiency of the valve function, and can maintain the structural integrity in repeated contraction-expansion cycles, providing an ideal solution for long-term stable application in a physiological environment.

This invention belongs to the field of traditional Chinese medicine (TCM) technology, specifically relating to a TCM composition with detoxifying and uterus-warming effects and its application in the preparation of external products. The medicinal component of this external TCM product is composed of fenugreek, amethyst, rose, pomegranate seed, centella asiatica, long pepper, five-finger peach, lycopodium, litchi seed, and achyranthes bidentata. Animal experiments show that this product can significantly reduce the number of writhing movements in animals with cold-induced blood stasis type dysmenorrhea, lower COX-2 and PGE2 levels in the uterus, and improve peritoneal inflammation, demonstrating good detoxifying, blood stasis-removing, menstruation-regulating, and pain-relieving effects. Regarding blood rheology, it exhibits the effects of inhibiting platelet aggregation, dilating blood vessels, reducing blood viscosity, and balancing TXA2 and PGI2 levels, reflecting its effects of warming the kidneys and uterus, and strengthening the body's foundation. In summary, the TCM composition of this invention and its prepared external product can warm the kidneys and uterus, promote diuresis and eliminate turbidity, providing a novel TCM external application solution for the clinical treatment of cold-induced blood stasis type dysmenorrhea.

The invention relates to an application of a patent medicine Tenapanor approved by FDA in preparing a medicament for resisting platelet and arterial thrombosis. The medicament can be used for effectively inhibiting platelet activation and aggregation and arterial thrombosis block formation. The invention relates to an FDA approved patent medicine Tanipanol capable of effectively inhibiting platelet activation and aggregation induced by a natural agonist ADP and carotid artery and mesenteric artery thrombosis. Tanipamox is used as a novel candidate drug for resisting formation of platelets and arterial thrombosis blocks in fundamental research of thrombotic diseases, and has potential application value in prevention and treatment of arterial thrombosis related diseases.

The present disclosure relates to inhibition of platelet absorption. Cardiovascular grafts with highly reduced thrombosis are provided. The cardiovascular graft is an electrospun nonwoven web produced from a supramolecular polymer of large diameter fibers. The cardiovascular graft can be implanted in a human body as a vascular graft to allow blood vessel bypass / reconstruction, or repeated venous access for dialysis treatment, as well as other small diameter vascular disorders.

The present application provides a Bifidobacterium breve. The strain has high yield of acetoin and has milk clotting function. The present application provides a fermenting agent comprising the Bifidobacterium breve. The preparation method of the fermenting agent is also provided. The present application also provides a fermented ovine colostrum, which contains a plurality of functional polypeptides. The present application also provides a preparation method of the fermented ovine colostrum. The method can simultaneously ensure high retention rate of nutrients in the ovine colostrum. The present application also provides a polypeptide. The polypeptide can inhibit angiotensin converting enzyme activity, improve vascular endothelial function or inhibit platelet aggregation, and has cardiovascular protection ability. The present application also provides a polypeptide composition. The present application also provides application of the Bifidobacterium breve, the polypeptide and / or the fermented ovine colostrum in the field of food or medicine for helping to enhance immunity.

The present application belongs to the technical field of biological medicine, and particularly relates to an earthworm anti-platelet oligopeptide and application thereof. The present application is an anti-platelet oligopeptide discovered by combining a Pheretima aspergillum (E. Perrier) transcriptome database with active-oriented separation. The oligopeptide can not only inhibit the activation and aggregation of platelets, but also effectively inhibit the adhesion and expansion of platelets, and can effectively inhibit various functions of platelets at an in-vitro level. In summary, the oligopeptide of the present application can significantly inhibit platelets, and is suitable for anti-thrombus drug research and development.

Disclosed in the present invention are a tetracycline derivative and the use thereof. The tetracycline derivative of the present invention can inhibit platelet aggregation, and the compound has broad application prospects in the preparation of drugs for preventing or treating stroke.

The invention discloses a lophatherum gracile extract in preparation of a medicine for treating and preventing thrombosis and application of the lophatherum gracile extract in preparation of the medicine for treating and preventing thrombosis, and the medicine comprises the lophatherum gracile extract. The common lophatherum herb extract can inhibit platelet agonist-induced platelet blood clot formation so as to prevent and treat thrombosis, and can inhibit a platelet agonist-induced platelet aggregation function so as to prevent and treat thrombosis. A platelet activation function induced by a platelet agonist can be inhibited so as to prevent and treat thrombosis, and platelet microtubule morphological change induced by the platelet agonist can be inhibited so as to prevent and treat thrombosis; the invention proves that the lophatherum gracile extract has the effects of inhibiting platelet aggregation, activation, particle release and microtubule morphological change for the first time, has small toxic and side effects, provides a new research and development direction for clinical treatment of thrombotic diseases, and shows that the lophatherum gracile extract can be used as a new type of health care product medicine for preventing thrombotic diseases.

The present application relates to composition for nourishing the kidneys and its preparation method. More specifically, the present application relates to an Oyster peptide kidney-nourishing formula composition and preparation method. The composition and preparation method are designed to address the technical issues in traditional Chinese medicine where the kidney-nourishing effects are slow to appear, treatment takes a long time, boiled medicine has a poor taste, and it's inconvenient to carry. An Oyster peptide kidney-nourishing formula composition, comprising the following medicines: oyster peptide, pumpkin seed extra, epimedium extract, maca extract, tribulus terrestris extract, eurycomanone, arginine, lycopene, VB2, VB6, selenium and zinc. The product created by this application has several functions such as increasing male serum testosterone levels, regulating blood lipids, inhibiting platelet aggregation, improving symptoms of hyperglycemia, enhancing human immunity, and promoting metabolism.

The present invention discloses a synthesis method and application of a class of chiral N-(1-substituted-allyl)amines. This method successfully implements a molybdenum-catalyzed asymmetric allylic amination reaction, avoiding the use of complex and difficult-to-synthesize chiral phosphine ligands. The method offers advantages such as a wide substrate range, specific stereoselectivity, a single chemical reaction site, readily available raw materials, simple operation, and mild reaction conditions. This method provides more options for the green synthesis of chiral allylic amines. The method can also be applied to the total synthesis of natural products. Furthermore, the total synthesis of clopidogrel, a drug that inhibits platelet aggregation, has been demonstrated.

The present invention provides in certain embodiments methods of inhibiting platelet function or thrombosis, inhibiting pyruvate kinase M2 (PKM2) dimerization, and / or treating a disease associated with thrombosis by administering a composition comprising a dimeric pyruvate kinase M2 (PKM2) inhibitor in a patient in need thereof.

Multivalent anti-platelet glycoprotein I(b)alpha antibodies can cause severe side effects. The present disclosure provides humanized antibodies specifically recognizing glycoprotein I(b)alpha and lacking a Fc portion, therefore Bleeding Time do not interact with Fc receptor. The humanized antibodies are capable of preventing platelet activation and aggregation, and reducing thrombus size / growth and prevent vessel occlusion. They can be also very useful to decrease platelet-tumor cell interaction and decrease tumor metastasis. At therapeutic doses, the humanized antibodies lack the ability to induce platelet activation, induce thrombocytopenia; and / or prolong bleeding time.